The American Journal of Managed Care2h
First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA
The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...
Health on MSN1d
What Is Visceral Fat—and How Does It Affect Your Health?
Medically reviewed by Kashif J. Piracha, MD Subcutaneous fat is the fat right under your skin—the kind you can pinch. It ...
Managed Healthcare Executive3h
Alhemo Once-Daily Treatment for Hemophilia A, B with Inhibitors FDA Approved
The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...
oncnursingnews3h
Subcutaneous Amivantamab in Practice: Clinical Insights and AE Management
Panelists discuss how the availability of subcutaneous amivantamab influences nursing approaches to patient care and education, with Squires sharing strategies for ensuring patients understand the new ...
FiercePharma9h
Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
emjreviews.com2d
Concizumab Shows Promise as a Subcutaneous Prophylaxis for Haemophilia A and B
A PHASE 3 clinical trial, explorer8, has demonstrated the efficacy and safety of concizumab, a monoclonal antibody in ...
BioSpace6d
J&J’s FDA Bid for Subcutaneous Rybrevant Falls Short
The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with ...
Hosted on MSN6d
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
Johnson & Johnson JNJ announced that the FDA has issued a complete response letter (“CRL”) to its biologics license ...